Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: Experimental studies in primates

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue SUPPL. 1, 2004, Pages 41-47

  Jeske, Walter ^a,b   Fareed, Jawed ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Heparin; Low molecular weight heparin (LMWH); Pharmacokinetics; Tinzaparin; Tissue factor pathway inhibitor (TFPI); Unfractionated heparin (UFH)

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; TINZAPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ATHEROSCLEROTIC PLAQUE; BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPOLYMERIZATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOSTASIS; NONHUMAN; PRIMATE; PRIORITY JOURNAL; THROMBOEMBOLISM; TREATMENT INDICATION;

ANIMALS; BIOLOGICAL AVAILABILITY; FACTOR XA; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; MACACA MULATTA; MALE; PHARMACOKINETICS; PROTHROMBIN;

EID: 1842451674     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-823002     Document Type: Conference Paper

References (25)

1. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM. Are the available low-molecular-weight heparin preparations the same? Semin Thromb Hemost 1996;22(suppl 1):77-91
2. Casu B, Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost 1999;25(suppl 3):17-25
3. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001;119:64S-94S
4. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996;124:619-626
5. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700
6. Heit JA, Berkowitz SD, Bona R, Ardeparin Arthroplasty Study Group, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Thromb Haemost 1997;77:32-38
7. Koppenhagen K, Adolf J, Matthes M, et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 1992;67:627-630
8. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (fragmin) in high-risk pregnancies. Thromb Haemost 1997;77:39-43
9. Fareed J, Callas DD, Hoppensteadt D, Jeske W, Walenga JM. Recent developments in antithrombotic agents. Expert Opin Investig Drugs 1995;4:389-412
10. Godwin J. Use of low molecular weight heparins in malignancy-related thromboembolic disorders: a clinical review. Clin Appl Thromb Hemost 1996;2(suppl 1):S28-S34
11. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402
12. Rabah MM, Premmereur J, Graham M, et al. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395
13. Kereiakes DJ, Grines C, Fry E for the NICE 1 and NICE 4 Investigators. National investigators collaborating on enoxaparin. J Invasive Cardiol 2001;13:272-278
14. Hoppensteadt DA, Jeske W, Fareed J, Bermes EW. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin. Blood Coagul Fibrinolysis 1995;6:S57-S64
15. Jeske W, Hoppensteadt D, Klauser R, et al. Effect of repeated aprosulate and enoxaparin administration on TFPI antigen levels. Blood Coagul Fibrinolysis 1995;6:119-124
16. Sandset PM, Abildgaard P, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988;50:803-813
17. Alban S. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost 2001;7:503-511
18. Antman EM, McCabe CH, Marble SJ, et al. Dose ranging trial of enoxaparin for unstable angina: results of TIMI 11A. Circulation 1996;94:I-554 (abst)
19. Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-568
20. Cohen M, Demers C, Gurfinkel E, Fromell E, Langer A, Turpie AGG. ESSENCE Group: primary end point analysis from the ESSENCE trial: enoxaparin vs unfractionated heparin in unstable angina and non-Q wave infarction. Circulation 1996;94:I-554 (abst)
21. Neely JL, Carlson SS, Lenhart SE. Tinzaparin sodium: a low-molecular-weight heparin. Am J Health Syst Pharm 2002;59:1426-1436
22. Samama MM, Gerotziafas GT. Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost 2000;26(suppl 1):31-38
23. Iqbal O, Jeske W, Bacher P, Hoppensteadt DA, Walenga JM, Fareed F. A comparison of the pharmacokinetic and pharmacodynamic profiles of clexane and lovenox in dogs. Semin Thromb Hemost 1993;19(suppl 1):199-209
24. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry 1987;26:6454-6461
25. Laurent TC, Tengblad A, Thunberg L, Hook M, Lindahl U. The molecular weight dependence of the anticoagulant activity of heparin. Biochem J 1978;175:691-701